Monte Rosa Therapeutics, Inc. (GLUE) vs QuidelOrtho Corporation (QDEL)
A side-by-side comparison of Monte Rosa Therapeutics, Inc. and QuidelOrtho Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GLUE
Monte Rosa Therapeutics, Inc.
$10.15HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
QDEL
QuidelOrtho Corporation
$12.33HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
Total return — GLUE vs QDEL
growth of $100 · dividends reinvested · last 5yGLUE -51.5% (-13.5%/yr)QDEL -89.3% (-36.1%/yr)GLUE compounded faster over this window
GLUE QDEL
GLUE vs QDEL: by the numbers
- •GLUE is the larger company ($857M vs $841M market cap).
- •Both run net losses; QDEL's is the smaller (-39.20% vs -560.85% net margin).
Metrics side by side
Valuation
| Metric | GLUE | QDEL |
|---|---|---|
| Forward P/E | N/A | 15.96 |
| P/S ratio | 29.84 | 0.31 |
| P/B ratio | 1.76 | 0.47 |
Profitability
| Metric | GLUE | QDEL |
|---|---|---|
| Gross margin | 92.94% | 44.60% |
| Operating margin | -43.83% | -30.67% |
| Net margin | -560.85% | -39.20% |
| ROE | -33.06% | -59.07% |
| ROIC | -28.69% | -16.05% |
Growth (annualized)
| Metric | GLUE | QDEL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 7.14% |
| Total return CAGR (5Y) | -12.32% | -38.12% |
Frequently asked
- How have GLUE and QDEL total returns compared?
- Over the past 5 years, GLUE delivered -12.32% and QDEL delivered -38.12% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.